Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Breeze Holdings Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
YD Bio Announces Closing of Business Combination and Listing on the Nasdaq Global Market
Details : The Company is advancing corneal stem cell and exosome technologies for the treatment of ocular diseases such as dry eye syndrome, glaucoma, and corneal injury.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 30, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Breeze Holdings Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger